{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:14:38Z","timestamp":1789427678300,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"The Leona M and Harry B Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ebiom.2026.106298","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:13:17Z","timestamp":1779225197000},"page":"106298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Partial restoration of counterregulatory circulating glucagon by dapagliflozin and low-dose glibenclamide in men with type 1 diabetes: in vitro studies and randomised clinical crossover trial"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0845-1370","authenticated-orcid":false,"given":"Rui","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Spiliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1551-4114","authenticated-orcid":false,"given":"Haiqiang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Kothegala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-2093","authenticated-orcid":false,"given":"Caroline","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkemjika","family":"Abiakam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8492-358X","authenticated-orcid":false,"given":"Sarah","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2797-3385","authenticated-orcid":false,"given":"Amanda","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-0767","authenticated-orcid":false,"given":"Patrik","family":"Rorsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2026.106298_bib1","series-title":"Human Metabolism: A Regulatory Perspective","first-page":"392","author":"Frayn","year":"2019"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106298_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s42255-022-00725-3","article-title":"Metabolic messengers: glucagon","volume":"5","author":"MacDonald","year":"2023","journal-title":"Nat Metab"},{"issue":"4108","key":"10.1016\/j.ebiom.2026.106298_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1126\/science.182.4108.171","article-title":"Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect","volume":"182","author":"Gerich","year":"1973","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106298_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrendo.2014.170","article-title":"Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications","volume":"10","author":"Frier","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106298_bib5","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/dom.13690","article-title":"Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: a UK multisite 12-month prospective observational study","volume":"21","author":"Dunkley","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106298_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","article-title":"Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management","volume":"7","author":"Amiel","year":"2019","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106298_bib7","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00125-014-3279-8","article-title":"ATP-regulated potassium channels and voltage-gated calcium channels in pancreatic alpha and beta cells: similar functions but reciprocal effects on secretion","volume":"57","author":"Rorsman","year":"2014","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106298_bib8","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s42255-024-01139-z","article-title":"Loss of electrical beta-cell to delta-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes","volume":"6","author":"Hill","year":"2024","journal-title":"Nat Metab"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106298_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2337\/db23-0809","article-title":"Nicotinic signaling stimulates glucagon secretion in mouse and human pancreatic alpha-cells","volume":"74","author":"Hamilton","year":"2025","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106298_bib10","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.2337\/db17-1102","article-title":"Adrenaline stimulates glucagon secretion by Tpc2-Dependent Ca(2+) mobilization from acidic stores in pancreatic alpha-cells","volume":"67","author":"Hamilton","year":"2018","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106298_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cmet.2010.04.007","article-title":"GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis","volume":"11","author":"De Marinis","year":"2010","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106298_bib12","first-page":"428","article-title":"Characterisation of sulphonylurea and ATP-regulated K+ channels in rat pancreatic A-cells","volume":"438","author":"Bokvist","year":"1999","journal-title":"Pflugers Arch"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106298_bib13","doi-asserted-by":"crossref","first-page":"958","DOI":"10.2337\/diabetes.51.4.958","article-title":"Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response","volume":"51","author":"Banarer","year":"2002","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106298_bib14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2337\/diabetes.54.3.757","article-title":"Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans","volume":"54","author":"Raju","year":"2005","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106298_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/jc.2003-031011","article-title":"The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency","volume":"89","author":"Ostergard","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106298_bib16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1210\/jcem-54-2-459","article-title":"Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects","volume":"54","author":"Bohannon","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106298_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106298_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106298_bib19","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.TP.0000140882.53773.DC","article-title":"Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture","volume":"78","author":"Goto","year":"2004","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106298_bib20","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00125-015-3598-4","article-title":"Human islet function following 20 years of cryogenic biobanking","volume":"58","author":"Manning Fox","year":"2015","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106298_bib21","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1007\/BF01971460","article-title":"Interaction of sulfonylurea with the pancreatic B-cell","volume":"40","author":"Gylfe","year":"1984","journal-title":"Experientia"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106298_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00169252","article-title":"Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cells","volume":"337","author":"Zunkler","year":"1988","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ebiom.2026.106298_bib23","series-title":"Annex I Summary of Product Characteristics","year":"2012"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106298_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cmet.2013.10.014","article-title":"Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes","volume":"18","author":"Zhang","year":"2013","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106298_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143011","article-title":"Residual beta cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia","volume":"131","author":"Gubitosi-Klug","year":"2021","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106298_bib26","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/dom.14740","article-title":"Reducing hyperglucagonaemia in type 2 diabetes using low-dose glibenclamide: results of the LEGEND-A pilot study","volume":"24","author":"Spiliotis","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ebiom.2026.106298_bib53","series-title":"Statistical Issues in Drug Development","author":"Senn","year":"2007"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106298_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ije\/29.1.158","article-title":"Principles of multilevel modelling","volume":"29","author":"Greenland","year":"2000","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ebiom.2026.106298_bib27","series-title":"Practical Statistics for the Biological Sciences. Simple Pathways to Statistical Analysis","first-page":"168","author":"Ashcroft","year":"2003"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106298_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/BF00657506","article-title":"Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beta-cells","volume":"407","author":"Trube","year":"1986","journal-title":"Pflugers Arch"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106298_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41467-018-08193-8","article-title":"Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion","volume":"10","author":"Vergari","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106298_bib31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1016\/j.ebiom.2026.106298_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1463-1326.2011.01450.x","article-title":"Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?","volume":"13","author":"Walker","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106298_bib33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.cmet.2009.02.007","article-title":"Insulin signaling in alpha cells modulates glucagon secretion in vivo","volume":"9","author":"Kawamori","year":"2009","journal-title":"Cell Metab"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106298_bib34","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/db08-1084","article-title":"The barrier of hypoglycemia in diabetes","volume":"57","author":"Cryer","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ebiom.2026.106298_bib35","article-title":"Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes","volume":"1010","author":"Kim","year":"2021","journal-title":"Elife"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106298_bib36","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.2337\/diabetes.53.11.2836","article-title":"Palmitate stimulation of glucagon secretion in mouse pancreatic alpha-cells results from activation of L-type calcium channels and elevation of cytoplasmic calcium","volume":"53","author":"Olofsson","year":"2004","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106298_bib37","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00125-014-3213-0","article-title":"GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans","volume":"57","author":"Stone","year":"2014","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106298_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s42255-025-01422-7","article-title":"Antecedent hypoglycaemia impairs glucagon secretion by enhancing somatostatin-mediated negative feedback control","volume":"8","author":"Gao","year":"2026","journal-title":"Nat Metab"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106298_bib39","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2337\/db24-1053","article-title":"Metabolic and paracrine heterogeneity of pancreatic glucagon-secreting alpha-cells","volume":"44","author":"Dou","year":"2025","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106298_bib40","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.cmet.2018.10.003","article-title":"Dysregulation of glucagon secretion by hyperglycemia-induced sodium-dependent reduction of ATP production","volume":"29","author":"Knudsen","year":"2019","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106298_bib41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.diabet.2018.06.005","article-title":"SGLT2 inhibition and glucagon secretion in humans","volume":"44","author":"Saponaro","year":"2018","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106298_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s42255-019-0158-0","article-title":"Somatostatin secretion by Na(+)-dependent Ca(2+)-induced Ca(2+) release in pancreatic delta-cells","volume":"2","author":"Vergari","year":"2020","journal-title":"Nat Metab"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106298_bib43","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2337\/dc20-2887","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2 diabetes: a randomized, double-blind crossover trial","volume":"44","author":"Op den Kamp","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ebiom.2026.106298_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155396","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial","volume":"140","author":"Veelen","year":"2023","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106298_bib45","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2337\/db21-0769","article-title":"SGLT2 inhibition increases fasting glucagon but does not restore the counterregulatory hormone response to hypoglycemia in participants with type 1 diabetes","volume":"71","author":"Boeder","year":"2022","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106298_bib47","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S2213-8587(19)30265-7","article-title":"NICE guidance on dapagliflozin with insulin for type 1 diabetes","volume":"7","author":"Adler","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ebiom.2026.106298_bib48","article-title":"Type 1 diabetes drug was withdrawn because of a \u201ccommercial conflict of interest,\u201d charity argues","volume":"376","author":"Mahase","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ebiom.2026.106298_bib49","article-title":"A network meta-analysis of the dose-response effects of dapagliflozin on efficacy and safety in adults with type 1 diabetes","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106298_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102815","article-title":"Gender representation in drug development studies for diabetes mellitus. A systematic review","volume":"17","author":"Herskind","year":"2023","journal-title":"Diabetes Metab Syndr"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106298_bib51","doi-asserted-by":"crossref","first-page":"E1054","DOI":"10.1152\/ajpendo.2000.279.5.E1054","article-title":"Differential gender responses to hypoglycemia are due to alterations in CNS drive and not glycemic thresholds","volume":"279","author":"Davis","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106298_bib52","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(18)30136-0","article-title":"Glycaemic variability in diabetes: clinical and therapeutic implications","volume":"7","author":"Ceriello","year":"2019","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426001805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426001805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:26:06Z","timestamp":1783207566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426001805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"alternative-id":["S2352396426001805"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106298","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Partial restoration of counterregulatory circulating glucagon by dapagliflozin and low-dose glibenclamide in men with type 1 diabetes: in vitro studies and randomised clinical crossover trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106298"}}